Aaron (last name not provided)'s questions to Zoetis Inc (ZTS) leadership • Q4 2024
Question
An analyst from Morgan Stanley asked about veterinarian response to the Librela label change, its contribution to the 2025 guidance, and the key drivers for the projected margin improvement in 2025.
Answer
CEO Kristin Peck stated the Librela label update provided helpful transparency for veterinarians and confirmed that new pipeline products are not in the 2025 guidance. CFO Wetteny Joseph added that the OA pain franchise is expected to contribute to double-digit growth for key franchises. He attributed the 2025 margin improvement to the accretive MFA divestiture, favorable product mix, and pricing, partially offset by FX headwinds.